{"id":78552,"date":"2026-09-03T17:52:51","date_gmt":"2026-09-03T09:52:51","guid":{"rendered":"https:\/\/flcube.com\/?p=78552"},"modified":"2026-09-03T17:52:52","modified_gmt":"2026-09-03T09:52:52","slug":"nmpa-expands-conformance-evaluations-to-eye-drops-patches-and-sprays-raising-the-bar-for-generic-drugs-in-non-oral-dosage-forms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78552","title":{"rendered":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>National Medical Products Administration (NMPA)<\/strong> announced a decision to carry out quality and efficacy <strong>conformance evaluations<\/strong> for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to <strong>eye drops<\/strong>, patches, sprays, and other dosage forms. The move marks the next phase of China&#8217;s decade\u2011long generic drug quality upgrade \u2014 with <strong>eye drops<\/strong> evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.<\/p>\n\n\n\n<h2 id=\"h-policy-implementation-timeline\" class=\"wp-block-heading\">Policy Implementation Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Issuing Authority<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong><\/td><\/tr><tr><td>Policy Scope<\/td><td>Quality and efficacy conformance evaluations for chemical drugs in non\u2011oral\u2011solid \/ non\u2011injection dosage forms<\/td><\/tr><tr><td>Dosage Forms Covered (Phased)<\/td><td><strong>Eye drops<\/strong>, patches, sprays, and other dosage forms<\/td><\/tr><tr><td>Eye Drops<\/td><td>Evaluations initiated as of the announcement date (Sept 2, 2026)<\/td><\/tr><tr><td>Patches and Sprays<\/td><td>Evaluations to launch on July 1, 2027<\/td><\/tr><tr><td>Regulatory Basis<\/td><td>Extension of the existing conformance evaluation framework for generic drugs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-evaluation-requirements-amp-clinical-trial-provisions\" class=\"wp-block-heading\">Evaluation Requirements &amp; Clinical Trial Provisions<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>General Standard:<\/strong> Generic preparations must demonstrate consistency in quality and efficacy versus reference products, typically through pharmaceutical studies and\/or conventional bioequivalence studies<\/li>\n\n\n\n<li><strong>Complex Varieties Exception:<\/strong> For certain drugs where active pharmaceutical ingredients (APIs) or formulations are complex, pharmaceutical and bioequivalence studies alone may not fully demonstrate equivalence<\/li>\n\n\n\n<li><strong>Clinical Trial Requirement:<\/strong> In such cases, necessary clinical trials must be conducted to prove quality and efficacy equivalence between generic drugs and reference products<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Applicants may communicate specific clinical trial protocols with the Center for Drug Evaluation (CDE) through established communication channels<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Higher generic bar:<\/strong> Expanding conformance evaluations to complex dosage forms raises the technical threshold for generic manufacturers of <strong>eye drops<\/strong>, patches, and sprays \u2014 likely accelerating industry consolidation<\/li>\n\n\n\n<li><strong>Reference\u2011driven shakeout:<\/strong> Products unable to match reference drugs in quality and efficacy face potential market exit, while compliant generics gain prescribing confidence and procurement eligibility<\/li>\n\n\n\n<li><strong>Clinical trial burden:<\/strong> The requirement for clinical trials in complex\u2011formulation cases adds development cost and timelines, favoring technically stronger domestic players with established CDE engagement experience<\/li>\n\n\n\n<li><strong>Phased predictability:<\/strong> The staggered implementation \u2014 immediate for <strong>eye drops<\/strong>, 2027 for patches and sprays \u2014 gives manufacturers planning runway while signaling the <strong>NMPA&#8217;s<\/strong> long\u2011term commitment to full\u2011dosage\u2011form conformance coverage<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief describes a regulatory policy announcement and its potential industry implications. Interpretation of policy requirements and market outcomes involves uncertainty; companies should consult the official NMPA and CDE publications for definitive requirements. No investment decision should be made solely on the basis of this brief.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[14],"class_list":["post-78552","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nmpa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China&#039;s decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78552\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China&#039;s decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78552\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T09:52:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T09:52:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms\",\"datePublished\":\"2026-09-03T09:52:51+00:00\",\"dateModified\":\"2026-09-03T09:52:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NMPA\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78552#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78552\",\"name\":\"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-03T09:52:51+00:00\",\"dateModified\":\"2026-09-03T09:52:52+00:00\",\"description\":\"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China's decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78552\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78552#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms - Insight, China&#039;s Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China's decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78552","og_locale":"en_US","og_type":"article","og_title":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms","og_description":"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China's decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.","og_url":"https:\/\/flcube.com\/?p=78552","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-03T09:52:51+00:00","article_modified_time":"2026-09-03T09:52:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78552#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78552"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms","datePublished":"2026-09-03T09:52:51+00:00","dateModified":"2026-09-03T09:52:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78552"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NMPA"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78552#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78552","url":"https:\/\/flcube.com\/?p=78552","name":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-03T09:52:51+00:00","dateModified":"2026-09-03T09:52:52+00:00","description":"The National Medical Products Administration (NMPA) announced a decision to carry out quality and efficacy conformance evaluations for chemical drugs in dosage forms beyond oral solid preparations and injections, gradually expanding coverage to eye drops, patches, sprays, and other dosage forms. The move marks the next phase of China's decade\u2011long generic drug quality upgrade \u2014 with eye drops evaluations initiated immediately, and patches and sprays to follow on July 1, 2027.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78552#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78552"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78552#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Expands Conformance Evaluations to Eye Drops, Patches and Sprays, Raising the Bar for Generic Drugs in Non\u2011Oral Dosage Forms"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78552"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78552\/revisions"}],"predecessor-version":[{"id":78553,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78552\/revisions\/78553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}